PL2430051T3 - Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ - Google Patents

Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+

Info

Publication number
PL2430051T3
PL2430051T3 PL10720014T PL10720014T PL2430051T3 PL 2430051 T3 PL2430051 T3 PL 2430051T3 PL 10720014 T PL10720014 T PL 10720014T PL 10720014 T PL10720014 T PL 10720014T PL 2430051 T3 PL2430051 T3 PL 2430051T3
Authority
PL
Poland
Prior art keywords
hla
treating
compositions containing
related diseases
containing antibodies
Prior art date
Application number
PL10720014T
Other languages
English (en)
Inventor
Laurence Boumsell
Karine Lester
Séverine Loisel
Christian Berthou
Martine Cerruti
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université De Bretagne Occidentale
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université De Bretagne Occidentale, Centre National De La Recherche Scientifique (Cnrs) filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of PL2430051T3 publication Critical patent/PL2430051T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL10720014T 2009-05-14 2010-05-14 Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ PL2430051T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305434 2009-05-14
EP10720014.9A EP2430051B1 (en) 2009-05-14 2010-05-14 Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases

Publications (1)

Publication Number Publication Date
PL2430051T3 true PL2430051T3 (pl) 2017-04-28

Family

ID=41055306

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10720014T PL2430051T3 (pl) 2009-05-14 2010-05-14 Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+

Country Status (7)

Country Link
US (1) US8679500B2 (pl)
EP (1) EP2430051B1 (pl)
DK (1) DK2430051T3 (pl)
ES (1) ES2584916T3 (pl)
PL (1) PL2430051T3 (pl)
PT (1) PT2430051T (pl)
WO (1) WO2010145895A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516046A (ja) * 2011-05-26 2014-07-07 フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質ｃｄ５又はｃｄ６
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US11369663B2 (en) 2016-06-07 2022-06-28 Washington University Detection of CD5 and methods and compositions for modulating CD5
JP2021522303A (ja) 2018-05-03 2021-08-30 ゲンマブ ビー．ブイ． 抗体バリアントの組み合わせおよびその使用
JP2022514693A (ja) * 2018-12-21 2022-02-14 マルチチュード インコーポレーテッド Ｍｕｃ１８に特異的な抗体
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
WO2020247872A1 (en) * 2019-06-05 2020-12-10 Magenta Therapeutics, Inc. T-cell depleting therapies
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10162870A1 (de) * 2001-12-20 2003-07-10 Alexander Cherkasky Fusionsproteinen gegen B-Zell-Tumoren
EP1479760A1 (de) * 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
CA2599734C (en) * 2005-03-03 2014-01-28 Immunomedics, Inc. Humanized l243 antibodies

Also Published As

Publication number Publication date
EP2430051B1 (en) 2016-03-23
EP2430051A1 (en) 2012-03-21
DK2430051T3 (en) 2016-07-04
US20120121598A1 (en) 2012-05-17
ES2584916T3 (es) 2016-09-30
PT2430051T (pt) 2016-07-11
WO2010145895A1 (en) 2010-12-23
US8679500B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
HK1245344A1 (zh) 用於長片段閱讀測序的方法和組合物
IL255009A0 (en) Preparations that cause the help of t cells
PT2430051T (pt) Composições contendo anticorpos para tratar doenças relacionadas com células b ou t cd5+ hla- dr+
PT2475352E (pt) Composição contendo palmitoiletanolamida ultramicronizada
EP2430195A4 (en) COMPOSITIONS AND METHODS FOR STORING BIOLOGICAL SAMPLES
ZA201109364B (en) Stabilized protein compositions
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
IL216061A0 (en) Compositions and methods for antibodies targeting complement protein c3b
GB0905863D0 (en) Novel composition
HRP20150761T1 (hr) Postupak za proäśišä†avanje lipopeptida
IL214664A (en) Compositions are useful for treating hair-related conditions
IL213990A0 (en) Compositions for decontamination
EP2419446A4 (en) HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
IL216395A0 (en) Prothrombic complex composition
GB2476226B (en) Optimisation
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
EP2451982A4 (en) COMPOSITIONS AND METHODS FOR MAMMALS AND USE THEREOF
GB0917736D0 (en) Gel composition
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP2421952A4 (en) COMPOSITIONS FOR THE TRANSFECTION OF BIOMOLECULES IN CELLS
PL2503883T3 (pl) Kompozycja dezynfekująca
GB0900582D0 (en) Tropical composition
PL2263454T3 (pl) Kompozycja uzdatniająca
EP2415482A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METASTASIS